DP
Diadema Partners Portfolio holdings
AUM
$161M
This Quarter Return
+3.6%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$88.7M
AUM Growth
–
Cap. Flow
+$88.7M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
58.9%
Holding
86
New
54
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$9.05M |
| 2 |
AbbVie
ABBV
|
$8.89M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$6.68M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$5.6M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$4.2M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioNTech
BNTX
$24.7B
| $999K | 0.43% |
+8,767
| New | +$999K |
|
27
Viridian Therapeutics
VRDN
$1.5B
| $948K | 0.41% |
+49,478
| New | +$948K |
|
28
Vaxcyte
PCVX
$4.06B
| $819K | 0.35% |
+10,000
| New | +$819K |
|
29
Arcellx
ACLX
$3.93B
| $775K | 0.33% |
+10,100
| New | +$775K |
|
30
GH Research
GHRS
$856M
| $711K | 0.3% |
+101,502
| New | +$711K |
|
31
Geron
GERN
$880M
| $708K | 0.3% |
+200,000
| New | +$708K |
|
32
Cogent Biosciences
COGT
$1.8B
| $702K | 0.3% |
+90,000
| New | +$702K |
|
|
CLYM
33
Climb Bio, Inc. Common Stock
CLYM
$157M
| $674K | 0.29% |
+374,423
| New | +$674K |
|
34
Nektar Therapeutics
NKTR
$650M
| $650K | 0.28% |
+46,595
| New | +$650K |
|
35
UroGen Pharma
URGN
$858M
| $533K | 0.23% |
+50,000
| New | +$533K |
|
36
Alector
ALEC
$288M
| $452K | 0.19% |
+239,019
| New | +$452K |
|
37
argenx
ARGX
$44.8B
| $422K | 0.18% |
+679
| New | +$422K |
|
|
ONC
38
BeOne Medicines Ltd. American Depositary Shares
ONC
$35.4B
| $422K | 0.18% |
+30,000
| New | +$422K |
|
39
ProQR Therapeutics
PRQR
$250M
| $419K | 0.18% |
+158,023
| New | +$419K |
|
40
Erasca
ERAS
$403M
| $394K | 0.17% |
+156,973
| New | +$394K |
|
41
Zevra Therapeutics
ZVRA
$496M
| $351K | 0.15% |
+42,081
| New | +$351K |
|
42
ALX Oncology
ALXO
$55.7M
| $330K | 0.14% |
+197,680
| New | +$330K |
|
43
Eledon Pharmaceuticals
ELDN
$153M
| $312K | 0.13% |
+75,794
| New | +$312K |
|
44
Terns Pharmaceuticals
TERN
$598M
| $279K | 0.12% |
+50,370
| New | +$279K |
|
45
Gossamer Bio
GOSS
$559M
| $197K | 0.08% |
+217,987
| New | +$197K |
|
46
Candel Therapeutics
CADL
$274M
| $174K | 0.07% |
+20,000
| New | +$174K |
|
47
SAB Biotherapeutics
SABS
$20.7M
| $114K | 0.05% |
+30,000
| New | +$114K |
|
|
CMRX
48
DELISTED
Chimerix, Inc.
CMRX
| $101K | 0.04% |
+29,082
| New | +$101K |
|
49
Q32 Bio
QTTB
$20.1M
| $67.8K | 0.03% |
+19,700
| New | +$67.8K |
|
50
Edgewise Therapeutics
EWTX
$1.53B
| $36.3K | 0.02% |
+1,359
| New | +$36.3K |
|